¿ Organogenesis Inc., of Canton, Mass., said it placed an additional 300,000 shares at $17.625 per share, raising $5.3 million. The company raised net proceeds of $10.8 million in a placement in February.

¿ Oxford GlycoSciences plc, of Oxford, England, entered into a multi-target research collaboration with Bayer AG, of Leverkusen, Germany, in which OGS will apply its proteomics technology to identify disease-associated proteins as potential targets for drug discovery in respiratory disease. The two-year collaboration also will focus on identifying clinical markers of disease for use in drug development. Bayer has committed funding to OGS for two years and agreed to pay milestone payments and royalties.

¿ Quantum Dot Corp., of Palo Alto, Calif., entered into a research collaboration with the Genomics Institute of the Novartis Research Foundation. The goal is to use Quantum Dot nanocrystals to develop a variety of biological assays for proteome analysis and gene expression.

¿ Sangamo BioSciences Inc., of Point Richmond, Calif., signed a collaborative research agreement with Procter & Gamble Pharmaceuticals Co., of Cincinnati, under which Sangamo will provide specific Universal GeneTools to P&G for use in its internal research and validation programs. Financial terms were not disclosed.

¿ The Institute for Genomic Research, of Rockville, Md., said its investigators determined the complete genetic blueprint for Neisseria meningitidis. The study is reported in the March 10 issue of Science. Chiron Corp., of Emeryville, Calif., said it used the information on the microorganism¿s genetic structure to identify novel vaccine candidates against meningococcal B disease.

¿ Vertex Pharmaceuticals Inc., of Cambridge, Mass., sold $175 million of convertible subordinated notes due 2007 to qualified institutional buyers. The initial purchasers have an option to purchase additional $26.25 million in notes to cover overallotments. The notes are convertible into Vertex stock at a price equal to $80.64 per share, which represents a 12 percent premium to Wednesday¿s closing bid price of $72. The company announced the offering earlier this month. (See BioWorld Today, March 6, 2000, p. 5.)